Granted Patent B2

US 9,301,936 · App. 14/325,630 · Granted Apr 5, 2016

Abstract

Claims (52)

1. A pharmaceutical composition consisting essentially of a therapeutically effective amount of:

(a) tranexamic acid;

(b) one or more antibiotic(s);

(c) optionally, one or more anesthetic(s);

(d) optionally, one or more non-steroid anti-inflammatory drug(s) selected from the group consisting of ketorolac, ketoprofen, flurbiprofen, bromfenac, diclofenac and combinations thereof; and

(e) an excipient or carrier that facilitates transdermal non-mucosal administration.

2. The pharmaceutical composition of claim 1 , wherein the therapeutically effective amount of tranexamic acid is between 1-70% by weight of the composition.

3. The pharmaceutical composition of claim 1 , wherein the one or more antibiotic(s) are selected from the group consisting of sulfacetamide, mupirocin, erythromycin, sulfadiazine, mafenide, tetracycline, bacitracin, neomycin, and polymyxin B.

4. The pharmaceutical composition of claim 1 , wherein the one or more antibiotic(s) are selected from the group consisting of bacitracin, neomycin, and polymyxin B.

5. The pharmaceutical composition of claim 1 , wherein the excipient or carrier permits the composition to remain in contact with a bleeding wound.

6. The pharmaceutical composition of claim 5 , wherein the excipient or carrier comprises an ointment, a cream, a liniment, a paste, a patch, a lotion, a gel, a shampoo, a hydrogel, a liposome, a spray, an aerosol, a solution, a sponge, a film, a plaster, a surgical dressing, a bandage, or an emulsion.

7. The pharmaceutical composition of claim 1 , wherein the one or more anesthetic(s) are selected from the group consisting of lidocaine, proparacaine, procaine, tetracaine and combinations thereof.

8. The pharmaceutical composition of claim 1 , wherein the transdermal non-mucosal composition is selected from the group consisting of an ointment, a gel, a liniment, a paste, a film, a hydrogel, a liposome, a cream, a patch, and a spray.

9. A method for treating bleeding in a subject in need thereof comprising transdermally non-mucosally administering to the subject a pharmaceutical composition of claim 1 .

10. The method of claim 9 , wherein the therapeutically effective amount of tranexamic acid is between 1-70% by weight of the composition.

11. The method of claim 9 , wherein the one or more antibiotics are selected from the group consisting of sulfacetamide, mupirocin, erythromycin, sulfadiazine, mafenide, tetracycline, bacitracin, neomycin, and polymyxin B.

12. The method of claim 9 , wherein the one or more antibiotics are bacitracin, neomycin, and/or polymyxin B.

13. The method of claim 9 , wherein an anticoagulant has been or is to be administered to the subject.

14. The method of claim 9 , wherein the excipient or carrier permits the composition to remain in contact with said bleeding wound.

15. The method of claim 14 , wherein the excipient or carrier comprises an ointment, a cream, a liniment, a paste, a patch, a lotion, a gel, a shampoo, a hydrogel, a liposome, a spray, an aerosol, a solution, a sponge, a film, a plaster, a surgical dressing, a bandage, or an emulsion.

16. The method of claim 9 , wherein the one or more anesthetic(s) are selected from the group consisting of lidocaine, proparacaine, procaine, tetracaine and combinations thereof.

17. The method of claim 9 , wherein the one or more non-steroid anti-inflammatory drug(s) are selected from the group consisting of ketorolac, ketoprofen, flurbiprofen, bromfenac, diclofenac and combinations thereof.

18. The method of claim 9 , wherein the transdermal non-mucosal composition is selected from the group consisting of an ointment, a gel, a liniment, a paste, a film, a hydrogel, a liposome, a cream, a patch and a spray.

19. A kit comprising:

the pharmaceutical composition of claim 1 ;

two or more containers for housing the composition; and

instructions for use.

20. A pharmaceutical composition consisting of a therapeutically effective amount of tranexamic acid and an excipient or carrier that facilitates transdermal non-mucosal administration.

21. The pharmaceutical composition of claim 20 , further comprising one or more antibiotics.

22. The pharmaceutical composition of claim 20 , wherein the therapeutically effective amount of tranexamic acid is between 1-70% by weight of the composition.

23. The pharmaceutical composition of claim 21 , wherein the one or more antibiotics are selected from the group consisting of sulfacetamide, mupirocin, erythromycin, sulfadiazine, mafenide, tetracycline, bacitracin, neomycin, and polymyxin B.

24. The pharmaceutical composition of claim 21 , wherein the one or more antibiotics are selected from the group consisting of bacitracin, neomycin, and polymyxin B.

25. The pharmaceutical composition of claim 20 , wherein the excipient or carrier permits the composition to remain in contact with a bleeding wound.

26. The pharmaceutical composition of claim 25 , wherein the excipient or carrier comprises an ointment, a cream, a liniment, a paste, a patch, a lotion, a gel, a shampoo, a hydrogel, a liposome, a spray, an aerosol, a solution, a sponge, a film, a plaster, a surgical dressing, a bandage, or an emulsion.

27. The pharmaceutical composition of claim 20 , wherein the composition is an ointment, a gel, a liniment, a paste, a film, a hydrogel, a liposome, a cream, a patch, or a spray.

28. A method for treating bleeding in a subject in need thereof comprising transdermally non-mucosally administering to the subject a pharmaceutical composition, wherein the composition consists of a therapeutically effective amount of tranexamic acid and an excipient or carrier that facilitates the transdermal non-mucosal administration.

29. The method of claim 28 , wherein the pharmaceutical composition further comprises one or more antibiotics.

30. The method of claim 28 , wherein the pharmaceutical composition consists essentially of a therapeutically effective amount of tranexamic acid, one or more antibiotics, and an excipient or carrier that facilitates transdermal non-mucosal administration.

31. The method of claim 28 , wherein the therapeutically effective amount of tranexamic acid is between 1-70% by weight of the composition.

32. The method of claim 29 , wherein the one or more antibiotics are selected from the group consisting of sulfacetamide, mupirocin, erythromycin, sulfadiazine, mafenide, tetracycline, bacitracin, neomycin, and polymyxin B.

33. The method of claim 29 , wherein the one or more antibiotics are bacitracin, neomycin, and/or polymyxin B.

34. The method of claim 28 , wherein an anticoagulant has been or is to be administered to the subject.

35. The method of claim 28 , wherein the excipient or carrier permits the composition to remain in contact with said bleeding wound.

36. The method of claim 35 , wherein the excipient or carrier comprises an ointment, a cream, a liniment, a paste, a patch, a lotion, a gel, a shampoo, a hydrogel, a liposome, a spray, an aerosol, a solution, a sponge, a film, a plaster, a surgical dressing, a bandage, or an emulsion.

37. The method of claim 28 , wherein the composition is an ointment, a gel, a liniment, a paste, a film, a hydrogel, a liposome, a cream, a patch, or a spray.

38. A kit comprising: a pharmaceutical composition comprising a therapeutically effective amount of tranexamic acid; an excipient or carrier that facilitates transdermal non-mucosal administration; two or more containers for housing the composition and the excipient or carrier; and instructions for use.

39. The pharmaceutical composition of claim 1 , consisting essentially of a therapeutically effective amount of:

(a) tranexamic acid;

(b) one or more antibiotic(s);

(c) one or more anesthetic(s);

(d) one or more non-steroid anti-inflammatory drug(s) selected from the group consisting of ketorolac, ketoprofen, flurbiprofen, bromfenac, diclofenac and combinations thereof; and

(e) an excipient or carrier that facilitates transdermal non-mucosal administration.

Assignments (10)